TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Physical Activity in Older Adult MCO Members
Brief Summary: The purpose of this study is to determine whether a new phone and mail based coaching/support program that has been developed is more effective in helping people stay physically active than existing programs that are currently available to all HealthPartners members. We hypothesize that the intervention program will lead to a greater likelihood of physical activity maintenance among moderately active older adults than a usual care condition.


Options:
A: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group
B: Arm Label: CG; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health educational program | Arm Label: IG; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity intervention | Intervention Type: BEHAVIORAL; Name: Physical activity intervention; Assigned to Arm(s): IG | Intervention Type: BEHAVIORAL; Name: Health educational program; Assigned to Arm(s): CG
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintaining Physical Activity in Older Adult MCO Members
Brief Summary: The purpose of this study is to determine whether a new phone and mail based coaching/support program that has been developed is more effective in helping people stay physically active than existing programs that are currently available to all HealthPartners members. We hypothesize that the intervention program will lead to a greater likelihood of physical activity maintenance among moderately active older adults than a usual care condition.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Phone counseling with written materials | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Phone counseling with written materials; Assigned to Arm(s): Intervention Group
B: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A
C: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zinc, Mental Health, and School Performance
Brief Summary: This study will determine whether supplements of the mineral zinc will improve mental health and school performance among schoolchildren in Guatemala.


Options:
A: Arm Label: Multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins-vitamins B-complex, C, and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins-vitamins B-complex, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mg zinc oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mg zinc oxide; Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Daily preventive Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily preventive Zn; placebo treatment | Arm Label: Therapeutic Zn; daily placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Therapeutic Zn; daily placebo | Arm Label: Intermittent Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Intermittent Zn; placebo treatment | Arm Label: Surveillance control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Surveillance control group | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily preventive Zn; placebo treatment; Assigned to Arm(s): Daily preventive Zn; placebo treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Therapeutic Zn; daily placebo; Assigned to Arm(s): Therapeutic Zn; daily placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Intermittent Zn; placebo treatment; Assigned to Arm(s): Intermittent Zn; placebo treatment | Intervention Type: OTHER; Name: Surveillance control group; Assigned to Arm(s): Surveillance control group
D: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins | Arm Label: Multivitamins + Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc, Drug: Multivitamins | Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Multivitamins + Zinc, Zinc | Intervention Type: DRUG; Name: Multivitamins; Assigned to Arm(s): Multivitamins, Multivitamins + Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HALT Progression of Polycystic Kidney Disease Study A
Brief Summary: The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two multicenter randomized clinical trials targeting different levels of kidney function: 1) early disease defined by GFR \>60 mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73 m2 (Study B; NCT01885559). Participants will be recruited and enrolled, either to Study A or B, over the first three years. Participants enrolled in Study A will be followed for at least 5 years, while those enrolled in Study B will be followed for five-to-eight years, with the average length of follow-up being six and a half years. The two concurrent randomized clinical trials differ by eligibility criteria, interventions and outcomes to be studied.


Options:
A: Arm Label: Study A, Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Telmisartan, Other: Low Blood Pressure Control | Arm Label: Study A, Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Standard Blood Pressure Control | Arm Label: Study A, Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lisinopril, Drug: Placebo, Other: Low Blood Pressure Control | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2, Study A, Arm 3, Study A, Arm 4 | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study A, Arm 3, Study A, Arm 4 | Intervention Type: OTHER; Name: Standard Blood Pressure Control; Assigned to Arm(s): Study A, Arm 1, Study A, Arm 3 | Intervention Type: OTHER; Name: Low Blood Pressure Control; Assigned to Arm(s): Study A, Arm 2, Study A, Arm 4
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): 1
C: Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lanreotide; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide
D: Arm Label: Sirolimus; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Sirolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.


Options:
A: Arm Label: Milnacipran then placebo; Type: OTHER; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo then milnacipran; Type: OTHER; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran then placebo, Placebo then milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran then placebo, Placebo then milnacipran
B: Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 50mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 100mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 200mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 400mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): desvenlafaxine succinate sustained-release (DVS SR) 100mg, desvenlafaxine succinate sustained-release (DVS SR) 200mg, desvenlafaxine succinate sustained-release (DVS SR) 400mg, desvenlafaxine succinate sustained-release (DVS SR) 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar pill | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Sugar pill; Assigned to Arm(s): Sugar pill
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Milnacipran 100mg; Assigned to Arm(s): Milnacipran

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Study to Evaluate the Efficacy of a Remote Digital Observation Camera Protocol in the Evaluation and Thrombolytic Treatment of Acute Stroke Patients in the Remote Hospital Setting
Brief Summary: The purpose of this trial is to determine if an experimental remote video camera system is an effective way for a stroke specialist to evaluate stroke patients from a distant site.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Technology Assisted Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Assisted Case Management | Intervention Type: BEHAVIORAL; Name: Technology-Assisted Case Management; Assigned to Arm(s): Technology Assisted Case Management
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
C: Arm Label: Telemedicine; Type: N/A; Interventions: N/A | Arm Label: Telephone; Type: N/A; Interventions: N/A
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing the Feasibility of Testing Domperidone's Effect on Breastfeeding in Women With Insufficient Breast Milk: An RCT Pilot Study
Brief Summary: This study is testing if a medication called domperidone will help women produce more milk so that they can keep breastfeeding and not use formula. The study is also testing what dose of domperidone works best to increase breast milk production.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herbal galactagogue; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Herbal galactagogue; Assigned to Arm(s): Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): N/A
C: Arm Label: study herbal tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: study herbal tea | Arm Label: herbal placebo tea; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: herbal placebo tea | Intervention Type: DIETARY_SUPPLEMENT; Name: study herbal tea; Assigned to Arm(s): study herbal tea | Intervention Type: DIETARY_SUPPLEMENT; Name: herbal placebo tea; Assigned to Arm(s): herbal placebo tea
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement
Brief Summary: This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.


Options:
A: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab
B: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
C: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
D: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement
Brief Summary: This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.


Options:
A: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
C: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
D: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.3 mg intravitreal ranibizumab | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: 2.0 mg intravitreal aflibercept | Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: 1.25 mg intravitreal bevacizumab | Intervention Type: DRUG; Name: 2.0 mg intravitreal aflibercept; Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: 1.25 mg intravitreal bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: 0.3 mg intravitreal ranibizumab; Assigned to Arm(s): Ranibizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement
Brief Summary: This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: MNPDR; Type: N/A; Interventions: N/A
C: Arm Label: Modified Early Treatment Diabetic Retinopathy Study (ETDRS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified-ETDRS photocoagulation | Arm Label: Mild Macular Grid (MMG); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mild Macular Grid photocoagulation | Intervention Type: PROCEDURE; Name: modified-ETDRS photocoagulation; Assigned to Arm(s): Modified Early Treatment Diabetic Retinopathy Study (ETDRS) | Intervention Type: PROCEDURE; Name: Mild Macular Grid photocoagulation; Assigned to Arm(s): Mild Macular Grid (MMG)
D: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser

Answer: A